shadow_tr

Myeloma Studies
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

CC4047-MM-007
A Phase III, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide, Bortezomib and Low-Dose Dexamethasone Versus Bortezomib and Low-Dose Mexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
More Information

BMT 99-1
Immuno-Transplantation for Lymphoid Malignancy Using Allogeneic Blood Stem Cells

E3A06 (CTSU)
Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
More Information

SWOG S1211
Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma
More information

SWOG S1304
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) With Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease
More Information

 

1430 Tulane Ave, New Orleans, LA 70112 504-988-5263 medsch@tulane.edu